Efficacy and Safety of Oral L-Ergothioneine Supplementation in Improving Ovarian Reserve: A Single-Center, Open-Label, Self-Controlled Clinical Trial

This single-center, open-label, self-controlled clinical trial demonstrates that oral L-ergothioneine supplementation (120 mg/day for three cycles) safely and significantly improves ovarian reserve markers (AMH, FSH, E2) and alleviates menstrual, sleep, and quality-of-life symptoms in women with diminished ovarian reserve, providing the first clinical evidence of its systemic benefits in reproductive aging.

The Gist

🌟 The Big Picture: A "Battery Recharge" for Your Ovaries

Imagine your ovaries are like a high-tech factory that produces eggs. As women age (especially between 35 and 45), this factory starts to slow down. The machines get rusty, the workers get tired, and the "output" (eggs) decreases. This is called Diminished Ovarian Reserve (DOR).

When the factory slows down, two bad things happen:

1. The Hormone Alarm: The brain (the boss) notices the factory is slow and starts screaming, sending out more "hurry up" signals (hormones like FSH). This causes stress, hot flashes, and bad sleep.
2. The Rust: Inside the factory, there is a buildup of "rust" called oxidative stress. This rust damages the machinery and makes the factory shut down faster.

The Study's Question: Can we clean off the rust and recharge the factory using a special nutrient called L-Ergothioneine (EGT)?

---

🔬 What Did They Do? (The Experiment)

• The Team: A group of researchers in China recruited 40 women aged 35–45 who had a slowing-down factory (low egg reserve) and were having trouble with their periods, sleep, or mood.
• The Treatment: Instead of a placebo (a fake pill), everyone took a real supplement: 120 mg of L-Ergothioneine every day. Think of this as a "super-rust remover" and "battery charger."
• The Duration: They took it for 3 months (about three menstrual cycles).
• The Safety Check: They made sure the women didn't get sick or have side effects.

---

📈 What Happened? (The Results)

After 3 months, the results were surprisingly good. Here is the breakdown using our factory analogy:

1. The Factory Output Increased (AMH Levels)

• What it is: AMH is a "report card" that tells us how many eggs are left in the factory.
• The Result: The score went up significantly. It was like the factory manager suddenly found a hidden stash of new raw materials. The women's bodies showed they had more eggs available than before.

2. The Boss Stopped Screaming (FSH Levels)

• What it is: FSH is the "hurry up" signal from the brain. When the factory is slow, the brain screams louder (high FSH), causing stress.
• The Result: The signal went down. The brain realized, "Oh, the factory is working better now, I don't need to scream as loud." This is a sign of a healthier balance.

3. The "Rust" Was Cleaned (Estrogen Levels)

• What it is: Estrogen is the fuel that keeps the factory running smoothly.
• The Result: Estrogen levels went up, meaning the factory was producing better quality fuel again.

4. The Workers Felt Better (Symptoms)

• The Result: The women didn't just see numbers change; they felt better.
  • Sleep: They slept much better (like a tired worker finally getting a good night's rest).
  • Mood & Hot Flashes: The "hot flashes" and mood swings (the factory overheating) stopped or got much better.
  • Periods: Their menstrual cycles became more regular and less painful.

---

🧠 Why Did This Work? (The Science Made Simple)

The researchers believe L-Ergothioneine is special because it has a GPS system.

• Normal Antioxidants: Most vitamins are like general cleaners; they clean the outside of the factory but can't get deep inside the machines.
• L-Ergothioneine (EGT): This nutrient has a special "key" (a transporter called OCTN1) that lets it walk right into the power plants (mitochondria) inside the egg cells.
• The Action: Once inside, it acts like a fire extinguisher, putting out the "rust" (oxidative stress) before it can damage the machinery. This allows the factory to run efficiently again, producing more eggs and better hormones.

⚠️ Important Caveats (The Fine Print)

While the results are exciting, the authors are being very honest about the limitations:

• No "Fake" Group: Everyone in the study took the real pill. There was no group taking a sugar pill to compare against. This means we can't be 100% sure it wasn't just the "placebo effect" (feeling better because you thought you were getting treatment), though the hormone changes suggest it was real.
• Small Group: Only 40 women were tested.
• Short Time: They only watched them for 3 months.

🏁 The Bottom Line

This study is a proof-of-concept. It's like a pilot test for a new engine. It shows that taking L-Ergothioneine is safe and might be a powerful way to:

1. Slow down the aging of the ovaries.
2. Improve sleep and mood in women approaching menopause.
3. Boost the body's natural egg supply.

The researchers are now saying, "This looks promising! Let's do a bigger, more rigorous study to confirm it."

Disclaimer: This summary is based on a preprint (a study that hasn't been fully peer-reviewed yet). Always consult a doctor before starting any new supplement, especially for reproductive health.

Technical Summary

1. Problem Statement

Ovarian Aging and Diminished Ovarian Reserve (DOR):
Ovarian aging is characterized by a progressive decline in ovarian reserve, oocyte quality, and hypothalamic-pituitary-ovarian (HPO) axis dysregulation. This condition, particularly in women aged 35–45, leads to infertility, menstrual irregularities, and early estrogen withdrawal causing peri-menopausal symptoms (e.g., hot flashes, sleep disturbances).
Pathophysiology:
The primary drivers of accelerated ovarian aging are oxidative stress (OS) and mitochondrial dysfunction. Reactive oxygen species (ROS) generated during ovulation accumulate due to declining endogenous antioxidant defenses, leading to granulosa cell apoptosis and depletion of the primordial follicle pool.
Therapeutic Gap:
While oxidative stress is a known driver, there is a lack of clinical evidence for targeted, high-efficiency antioxidants that can specifically accumulate in ovarian mitochondria to reverse or mitigate these effects. L-Ergothioneine (EGT), a unique sulfur-containing amino acid with a specific mitochondrial transporter (OCTN1), represents a promising candidate, but its clinical application for reproductive health remains unexplored.

2. Methodology

• Study Design: A single-center, open-label, self-controlled clinical trial (Proof-of-Concept).
• Setting: Qingdao Central Hospital of Rehabilitation University, China.
• Participants:
  • N: 40 women enrolled; 36 completed the study (90% adherence).
  • Criteria: Females aged 35–45 with DOR (Baseline AMH: 1.0–3.0 ng/mL) and menstrual disorders.
  • Exclusions: Severe organ disease, PCOS, thyroid dysfunction, pregnancy, or recent use of hormones/antioxidants.
• Intervention:
  • Agent: Oral L-Ergothioneine capsules (30 mg/capsule).
  • Dosage: 120 mg/day (4 capsules total: 2 morning, 2 evening).
  • Duration: Three consecutive menstrual cycles (approx. 3 months).
  • Safety Context: The ingredient holds FDA GRAS status (GRN No. 1270).
• Outcome Measures:
  • Primary: Change in serum Anti-Müllerian Hormone (AMH).
  • Secondary (Endocrine/Imaging): Basal FSH, Estradiol (E2), LH, PRL, Antral Follicle Count (AFC), Ovarian Volume.
  • Secondary (Clinical Symptoms): Modified Kupperman Index (KI), Pittsburgh Sleep Quality Index (PSQI), Menstrual Symptom Score, SF-36 (Quality of Life).
  • Safety: Adverse events (AEs), liver/kidney function, blood counts.
• Statistical Analysis: Paired t-tests/Wilcoxon signed-rank tests for pre-post comparisons; Pearson/Spearman correlations for hormone-symptom relationships; Subgroup analysis by age (35–39 vs. 40–45).

3. Key Contributions

• First Clinical Evidence: This is the first study to provide clinical proof-of-concept that oral EGT supplementation can improve ovarian reserve markers in women with DOR.
• Mechanistic Link: It establishes a correlation between endocrine restoration (specifically FSH reduction and E2 increase) and the amelioration of systemic symptoms (sleep and vasomotor issues), suggesting a physiological rather than placebo-driven mechanism.
• Safety Validation: Confirms the safety of a high-dose (120 mg/day) EGT regimen in a reproductive-age female population over a 3-month period.
• Stratified Insights: Provides preliminary data suggesting efficacy across different stages of reproductive aging (35–39 and 40–45), though larger cohorts are needed for definitive subgroup conclusions.

4. Key Results

A. Efficacy on Ovarian Reserve Markers (Objective):

• AMH: Significantly increased from 1.79 ± 0.71 to 2.47 ± 1.52 ng/mL ($p = 0.029$).
• FSH: Significantly decreased from 8.22 ± 2.93 to 7.05 ± 2.47 mIU/mL ($p = 0.032$), indicating reduced ovarian stress.
• Estradiol (E2): Significantly increased from 46.00 ± 22.70 to 63.46 ± 50.10 pg/mL ($p = 0.030$).
• AFC: Showed a positive upward trend (10.1 to 10.8), though not statistically significant within the short 3-month window ($p = 0.432$).

B. Efficacy on Clinical Symptoms (Subjective):

• Menopausal Symptoms (KI): Drastic reduction from 5.42 to 1.90 ($p < 0.0001$).
• Sleep Quality (PSQI): Significant improvement from 6.89 to 5.50 ($p < 0.0001$).
• Quality of Life (SF-36): Significant increase in scores ($p < 0.001$).
• Menstrual Health: A biphasic response was observed; initial cycles showed transient fluctuation, but by Cycle 3, a robust recovery in regularity and pain reduction was evident.

C. Correlation Analysis:

• A significant negative correlation was found between the change in FSH ($\Delta$FSH) and the change in E2 ($\Delta$E2) ($r = -0.46, p < 0.05$).
• Improvement in sleep quality ($\Delta$PSQI) was positively correlated with the reduction in FSH ($r = 0.43, p < 0.05$), linking hormonal stabilization directly to systemic relief.

D. Safety:

• Adverse Events: Zero treatment-related adverse events or dropouts due to side effects.
• Labs: No clinically significant deviations in liver, kidney, or hematological parameters. BUN decreased slightly but remained within normal physiological ranges.

5. Significance and Conclusion

• Mechanism of Action: The study supports the hypothesis that EGT, via the OCTN1 transporter, accumulates in ovarian mitochondria to scavenge ROS, thereby preserving granulosa cell function, reducing follicular apoptosis, and restoring the FSH/E2 feedback loop.
• Clinical Implication: Oral EGT (120 mg/day) presents a safe, non-hormonal nutritional strategy to delay reproductive aging, improve ovarian reserve, and alleviate peri-menopausal symptoms.
• Future Directions: While the pilot study is promising, the authors acknowledge limitations (open-label design, small sample size, short duration). The results provide the necessary effect size estimates to power future large-scale, randomized, double-blind, placebo-controlled trials (RCTs).

Conclusion: The study concludes that L-Ergothioneine effectively enhances serum AMH, optimizes the FSH/E2 balance, and provides substantial relief from sleep and vasomotor disturbances in women with diminished ovarian reserve, marking a significant step toward targeted antioxidant therapies for reproductive aging.